Table of Contents Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Wet (Neovascular / Exudative) Macular Degeneration Overview 10 Therapeutics Development 11 Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview 11 Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies 12 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies 19 Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development 24 Aciont Inc. 24 Allergan Plc 25 Amakem NV 26 Apellis Pharmaceuticals, Inc. 27 Apexigen, Inc. 28 Applied Genetic Technologies Corporation 29 Avalanche Biotechnologies, Inc. 30 Benitec Biopharma Limited 31 BIOCAD 32 Boehringer Ingelheim GmbH 33 Charlesson LLC. 34 Chong Kun Dang Pharmaceutical Corp. 35 Circadian Technologies Limited 36 Clanotech AB 37 Clearside BioMedical, Inc. 38 Coherus BioSciences, Inc. 39 Daiichi Sankyo Company, Limited 40 Delenex Therapeutics AG 41 Eleven Biotherapeutics Inc. 42 Exonate Limited 43 F. Hoffmann-La Roche Ltd. 44 Formycon AG 45 GTx, Inc. 46 iCo Therapeutics Inc. 47 Icon Bioscience, Inc. 48 Kala Pharmaceuticals, Inc. 49 Kodiak Sciences, Inc. 50 Mabion SA 51 Mitotech S.A. 52 Neurotech Pharmaceuticals, Inc. 53 Ocular Therapeutix, Inc. 54 Ohr Pharmaceutical Inc. 55 Ophthotech Corp. 56 Oxford BioMedica Plc 57 PanOptica, Inc. 58 Pfenex Inc. 59 Pfizer Inc. 60 pSivida Corp. 61 Quark Pharmaceuticals, Inc. 62 Regeneron Pharmaceuticals, Inc. 63 RegenxBio Inc. 64 RXi Pharmaceuticals Corporation 65 Santen Pharmaceutical Co., Ltd. 66 Sanwa Kagaku Kenkyusho Co., Ltd. 67 TRACON Pharmaceuticals, Inc. 68 TWi Pharmaceuticals, Inc. 69 Tyrogenex, Inc. 70 Xbrane Biopharma AB 71 Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics Assessment 72 Assessment by Monotherapy Products 72 Assessment by Combination Products 73 Assessment by Target 74 Assessment by Mechanism of Action 77 Assessment by Route of Administration 80 Assessment by Molecule Type 82 Drug Profiles 84 (aflibercept + nesvacumab) - Drug Profile 84 (aflibercept + rinucumab) - Drug Profile 85 abicipar pegol - Drug Profile 86 AC-301 - Drug Profile 89 ACX-107 - Drug Profile 90 aflibercept - Drug Profile 91 aflibercept biosimilar - Drug Profile 94 AGN-151200 - Drug Profile 95 ALG-1001 - Drug Profile 96 AMA-0428 - Drug Profile 98 APL-2 - Drug Profile 99 APX-003 - Drug Profile 101 APX-3330 - Drug Profile 102 AVA-101 - Drug Profile 104 AVA-201 - Drug Profile 106 avacincaptad pegol sodium - Drug Profile 107 AXT-108 - Drug Profile 109 bertilimumab - Drug Profile 110 Beta-LGND2 - Drug Profile 112 bevacizumab biosimilar - Drug Profile 114 BI-144807 - Drug Profile 115 brolucizumab - Drug Profile 116 C-16Y - Drug Profile 118 CLT-005 - Drug Profile 119 CLT-28643 - Drug Profile 120 cyclosporine - Drug Profile 121 DE-120 - Drug Profile 122 DLX-1008 - Drug Profile 123 DNX-214 - Drug Profile 124 Doxarubicin Pegylated - Drug Profile 125 Drug for Age Related Macular Degeneration - Drug Profile 126 Drug for Wet AMD and Dry AMD - Drug Profile 127 DS-7080 - Drug Profile 128 ENV-1305 - Drug Profile 129 ENV-705 - Drug Profile 130 GB-101 - Drug Profile 131 GB-102 - Drug Profile 132 Gene Therapy for Wet Age-related Macular Degeneration - Drug Profile 133 K-106 - Drug Profile 134 KSI-201 - Drug Profile 135 LHA-510 - Drug Profile 136 LMG-324 - Drug Profile 137 Monoclonal Antibody to Inhibit VEGF for Wet Macular Degeneration - Drug Profile 138 nesvacumab - Drug Profile 139 NT-503 - Drug Profile 141 NT-506 - Drug Profile 142 OCU-200 - Drug Profile 143 OLX-301 - Drug Profile 144 ONL-1204 - Drug Profile 145 OXB-201 - Drug Profile 146 PAN-90806 - Drug Profile 147 pegpleranib sodium - Drug Profile 149 PF-05206388 - Drug Profile 151 PF-655 - Drug Profile 152 plastoquinone decyl triphenylphosphonium bromide - Drug Profile 155 Protein to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile 157 ranibizumab - Drug Profile 158 ranibizumab biosimilar - Drug Profile 162 ranibizumab biosimilar - Drug Profile 163 ranibizumab biosimilar - Drug Profile 164 ranibizumab biosimilar - Drug Profile 166 ranibizumab biosimilar - Drug Profile 167 ranibizumab biosimilar - Drug Profile 168 ranibizumab biosimilar - Drug Profile 169 Recombinant Protein for Age Related Macular Degeneration - Drug Profile 170 Recombinant Proteins to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile 171 RG-7716 - Drug Profile 172 RGX-314 - Drug Profile 173 RXI-109 - Drug Profile 174 SK-1011 - Drug Profile 176 Small Molecules for Dry and Wet Age Related Macular Degeneration - Drug Profile 177 Small Molecules to Inhibit VEGF and PDGF for Wet AMD - Drug Profile 178 SPHINX-31 - Drug Profile 180 squalamine lactate - Drug Profile 181 Synthetic Peptides to Inhibit VEGF for Wet Adult Macular Degeneration - Drug Profile 184 TRC-105 - Drug Profile 185 triamcinolone acetonide - Drug Profile 188 TT-211 - Drug Profile 189 TT-231 - Drug Profile 190 VGX-300 - Drug Profile 191 X-82 - Drug Profile 193 Wet (Neovascular / Exudative) Macular Degeneration - Recent Pipeline Updates 195 Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects 235 Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects 235 Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products 238 Wet (Neovascular / Exudative) Macular Degeneration - Product Development Milestones 239 Featured News & Press Releases 239 Appendix 247 Methodology 247 Coverage 247 Secondary Research 247 Primary Research 247 Expert Panel Validation 247 Contact Us 247 Disclaimer 248

List of Tables Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H1 2016 17 Number of Products under Development by Companies, H1 2016 18 Number of Products under Development by Companies, H1 2016 (Contd..1) 19 Number of Products under Development by Companies, H1 2016 (Contd..2) 20 Number of Products under Development by Companies, H1 2016 (Contd..3) 21 Comparative Analysis by Late Stage Development, H1 2016 22 Comparative Analysis by Clinical Stage Development, H1 2016 23 Comparative Analysis by Early Stage Development, H1 2016 24 Products under Development by Companies, H1 2016 25 Products under Development by Companies, H1 2016 (Contd..1) 26 Products under Development by Companies, H1 2016 (Contd..2) 27 Products under Development by Companies, H1 2016 (Contd..3) 28 Products under Development by Companies, H1 2016 (Contd..4) 29 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Aciont Inc., H1 2016 30 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Allergan Plc, H1 2016 31 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Amakem NV, H1 2016 32 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Apellis Pharmaceuticals, Inc., H1 2016 33 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Apexigen, Inc., H1 2016 34 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Applied Genetic Technologies Corporation, H1 2016 35 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Avalanche Biotechnologies, Inc., H1 2016 36 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Benitec Biopharma Limited, H1 2016 37 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by BIOCAD, H1 2016 38 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Boehringer Ingelheim GmbH, H1 2016 39 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Charlesson LLC., H1 2016 40 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 41 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Circadian Technologies Limited, H1 2016 42 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clanotech AB, H1 2016 43 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clearside BioMedical, Inc., H1 2016 44 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Coherus BioSciences, Inc., H1 2016 45 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 46 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Delenex Therapeutics AG, H1 2016 47 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Eleven Biotherapeutics Inc., H1 2016 48 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Exonate Limited, H1 2016 49 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 50 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Formycon AG, H1 2016 51 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by GTx, Inc., H1 2016 52 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by iCo Therapeutics Inc., H1 2016 53 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Icon Bioscience, Inc., H1 2016 54 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Kala Pharmaceuticals, Inc., H1 2016 55 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Kodiak Sciences, Inc., H1 2016 56 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Mabion SA, H1 2016 57 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Mitotech S.A., H1 2016 58 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Neurotech Pharmaceuticals, Inc., H1 2016 59 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ocular Therapeutix, Inc., H1 2016 60 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ohr Pharmaceutical Inc., H1 2016 61 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ophthotech Corp., H1 2016 62 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Oxford BioMedica Plc, H1 2016 63 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by PanOptica, Inc., H1 2016 64 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfenex Inc., H1 2016 65 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfizer Inc., H1 2016 66 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by pSivida Corp., H1 2016 67 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Quark Pharmaceuticals, Inc., H1 2016 68 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 69 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by RegenxBio Inc., H1 2016 70 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by RXi Pharmaceuticals Corporation, H1 2016 71 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016 72 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2016 73 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016 74 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by TWi Pharmaceuticals, Inc., H1 2016 75 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Tyrogenex, Inc., H1 2016 76 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Xbrane Biopharma AB, H1 2016 77 Assessment by Monotherapy Products, H1 2016 78 Assessment by Combination Products, H1 2016 79 Number of Products by Stage and Target, H1 2016 81 Number of Products by Stage and Mechanism of Action, H1 2016 84 Number of Products by Stage and Route of Administration, H1 2016 87 Number of Products by Stage and Molecule Type, H1 2016 89 Wet (Neovascular / Exudative) Macular Degeneration Therapeutics - Recent Pipeline Updates, H1 2016 201 Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects, H1 2016 241 Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..1), H1 2016 242 Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..2), H1 2016 243 Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products, H1 2016 244 List of Figures Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H1 2016 17 Number of Products under Development by Companies, H1 2016 18 Comparative Analysis by Late Stage Development, H1 2016 22 Comparative Analysis by Clinical Stage Development, H1 2016 23 Comparative Analysis by Early Stage Products, H1 2016 24 Assessment by Monotherapy Products, H1 2016 78 Assessment by Combination Products, H1 2016 79 Number of Products by Top 10 Targets, H1 2016 80 Number of Products by Stage and Top 10 Targets, H1 2016 80 Number of Products by Top 10 Mechanism of Actions, H1 2016 83 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 83 Number of Products by Top 10 Routes of Administration, H1 2016 86 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 86 Number of Products by Top 10 Molecule Types, H1 2016 88 Number of Products by Stage and Top 10 Molecule Types, H1 2016 88

Aciont Inc. Allergan Plc Amakem NV Apellis Pharmaceuticals, Inc. Apexigen, Inc. Applied Genetic Technologies Corporation Avalanche Biotechnologies, Inc. Benitec Biopharma Limited BIOCAD Boehringer Ingelheim GmbH Charlesson LLC. Chong Kun Dang Pharmaceutical Corp. Circadian Technologies Limited Clanotech AB Clearside BioMedical, Inc. Coherus BioSciences, Inc. Daiichi Sankyo Company, Limited Delenex Therapeutics AG Eleven Biotherapeutics Inc. Exonate Limited F. Hoffmann-La Roche Ltd. Formycon AG GTx, Inc. iCo Therapeutics Inc. Icon Bioscience, Inc. Kala Pharmaceuticals, Inc. Kodiak Sciences, Inc. Mabion SA Mitotech S.A. Neurotech Pharmaceuticals, Inc. Ocular Therapeutix, Inc. Ohr Pharmaceutical Inc. Ophthotech Corp. Oxford BioMedica Plc PanOptica, Inc. Pfenex Inc. Pfizer Inc. pSivida Corp. Quark Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc. RegenxBio Inc. RXi Pharmaceuticals Corporation Santen Pharmaceutical Co., Ltd. Sanwa Kagaku Kenkyusho Co., Ltd. TRACON Pharmaceuticals, Inc. TWi Pharmaceuticals, Inc. Tyrogenex, Inc. Xbrane Biopharma AB